AMG 133 Weight Loss Trial
Summary
In this study, participants will take a new medication that will help them to lose weight and increase their satiety. This medication is called AMG 133. AMG 133 also helps people with Type 2 Diabetes control their blood sugars, and this study is for people with and without Type 2 Diabetes. Participants will visit with a study nurse to receive their medication, along with diet and exercise counselling, periodically for 68 weeks.
Eligibility
Eligible gender: Male, Female, Transgender, Other
Eligible ages: 18 to 100
Inclusion criteria:
To qualify to participate, participants must:
1. Be over 18 years of age
2. Have overweight or obesity, with a body mass index over 27kg/m2
3. Have tried without success to lose weight with diet and exercise in the past
Exclusion criteria:
We are not able to enroll participants who:
1. Have Type 1 Diabetes
2. Have had a change in weight of more than 5kg within the past 90 days
3. Have an unstable heart condition
Participate
Fill out the following form if you want to participate in this research
Collection of personal information
Your personal information is collected under
the authority of section 33(c) of the Freedom of Information and Protection of Privacy Act. If
you have any questions about the collection or use of this information, please visit our
Access to Information page.
Additional information
Contact information
To learn more or participate in this study, please contact the Study Coordinator, Michelle Smith.
Principal investigator:
David Lau
Clinical trial:
Yes
REB-ID:
REB22-1528